Current status of anti-angiogenesis therapy for prostate cancer.
Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.
Jiménez
Juan Antonio
JA
Urology Research Laboratory, Departments of Urology, Microbiology and Immunology, Walther Oncology Center, Indiana University Medical Center, Indianapolis, IN 46202, USA.
Kao
Chinghai
C
Raikwar
Sudhanshu
S
Gardner
Thomas A
TA